AI Verdict
REGN has stronger fundamentals based on our AI analysis.
ABBV vs REGN Fundamental Comparison
| Metric | ABBV | REGN |
|---|---|---|
| Revenue | $61.2B | $14.3B |
| Net Income | $4.2B | $4.5B |
| Net Margin | 6.9% | 31.4% |
| ROE | N/A | 14.4% |
| ROA | 3.2% | 11.1% |
| Current Ratio | 0.67x | 4.13x |
| Debt/Equity | N/A | 0.06x |
| EPS | $2.36 | $41.48 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
ABBV vs REGN: Frequently Asked Questions
Is ABBV or REGN a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), REGN has stronger fundamentals. ABBV is rated HOLD (70% confidence) while REGN is rated BUY (80% confidence). This is not investment advice.
How does ABBV compare to REGN fundamentally?
AbbVie Inc. has ROE of N/A vs REGENERON PHARMACEUTICALS, INC.'s 14.4%. Net margins are 6.9% vs 31.4% respectively.
Which stock pays higher dividends, ABBV or REGN?
ABBV has a dividend yield of N/A or no dividend while REGN has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in ABBV or REGN for long term?
For long-term investing, consider that ABBV has HOLD rating with 70% confidence, while REGN has BUY rating with 80% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about ABBV vs REGN?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For ABBV vs REGN, the AI consensus favors REGN based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.